摘要:
A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.
摘要:
A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.
摘要:
A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.
摘要:
A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.
摘要:
Heterocyclic compounds represented by the formula I and anti-malignant-tumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; Y represents C1-C6 alkyl; R1 represents morpholino (which may be substituted with one to four C1-C6 alkyl); and R2 and R3 each represent hydrogen atom or C1-C6 alkyl.
摘要:
Heterocyclic compounds represented by the formula I and anti-malignant-tumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; Y represents C1-C6 alkyl; R1 represents morpholino (which may be substituted with one to four C1-C6 alkyl); and R2 and R3 each represent hydrogen atom or C1-C6 alkyl.
摘要翻译:由式I表示的杂环化合物和含有杂环化合物的抗恶性肿瘤剂作为有效成分:其中X表示氮原子或CH; Y表示C 1 -C 6烷基; R 1表示吗啉代(其可以被一至四个C 1 -C 6烷基取代); R 2和R 3各自表示氢原子或C 1 -C 6烷基。
摘要:
The present invention relates to heterocyclic compounds represented by the formula I wherein X represents nitrogen atom or CH; R1 represents halogen atom or hydroxyl; R2 represents hydrogen atom, hydroxyl or amino; R3 represents morpholino (which may be substituted with one or two C1–C6 alkyl), pyrrolidinyl (which may be substituted with hydroxy C1–C6 alkyl) or NR6R7 [R6 represents C1–C6 alkyl and R7 represents piperidinyl (which may be substituted with C1–C6 alkyl)]; R4 and R5 each represents hydrogen atom or C1–C6 alkyl, with the proviso that R2 is hydrogen atom and R3 is pyrrolidinyl (which may be substituted with hydroxy C1–C6 alkyl) when R1 is hydroxyl
摘要:
The present application describes a method of treating prostate cancer, melanoma or hepatic cancer in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of the heterocyclic compound represented by Formula I or its pharmaceutically acceptable salt:
摘要:
The present invention relates to heterocyclic compounds represented by the formula I wherein X represents nitrogen atom or CH; R1 represents halogen atom or hydroxyl; R2 represents hydrogen atom, hydroxyl or amino; R3 represents morpholino (which may be substituted with one or two C1-C6 alkyl), pyrrolidinyl (which may be substituted with hydroxy C1-C6 alkyl) or NR6R7 [R6 represents C1-C6 alkyl and R7 represents piperidinyl (which may be substituted with C1-C6 alkyl)]; R4 and R5 each represents hydrogen atom or C1-C6 alkyl, with the proviso that R2 is hydrogen atom and R3 is pyrrolidinyl (which may be substituted with hydroxy C1-C6 alkyl) when R1 is hydroxyl
摘要翻译:本发明涉及由式I表示的杂环化合物,其中X表示氮原子或CH; R 1表示卤素原子或羟基; R 2表示氢原子,羟基或氨基; R 3表示吗啉代(其可以被一个或两个C 1 -C 6烷基取代),吡咯烷基(其可以被羟基 C 1 -C 6烷基)或NR 6 R 7 - [R 6 - 表示C 1 -C 6烷基,R 7表示哌啶基(其可以被C 1 -C 6烷基取代) 烷基)]; R 4和R 5各自代表氢原子或C 1 -C 6烷基,条件是R R 2是氢原子,R 3是吡咯烷基(其可以被羟基C 1 -C 6烷基取代) )当R 1为羟基时
摘要:
s-Triazine (1,3,5-triazine) is chemically modified to obtain s-triazine derivative effective for prevention and treatment of estrogen-dependent diseases.